What it sells
The full-stack AI CRO for drug discovery.
Business model breakdown
Buyer: who owns the budget?
UnverifiedClinical operations leaders at trial sponsors and hospitals.
Trigger: what makes them buy now?
UnverifiedRoutine trial feasibility, site activation, monitoring and safety work is manual and slow.
Workflow: what inputs become what output?
Thirteen agents run a study in lifecycle order (feasibility, site activation, monitoring, safety) with every consequential action held in one human review queue.
Distribution: how it reaches customers
Demo-led ("Book a demo").
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Fall 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.